# A Phase 2 Clinical Study in Subjects With Primary Progressive Multiple Sclerosis to Assess the Efficacy, Safety and Tolerability of Two Oral Doses of Laquinimod Either of 0.6 mg/Day or 1.5mg/Day (Experimental Drug) as Compared to Placebo

> **NCT02284568** · PHASE2 · COMPLETED · sponsor: **Teva Branded Pharmaceutical Products R&D, Inc.** · enrollment: 374 (actual)

## Conditions studied

- Primary Progressive Multiple Sclerosis

## Interventions

- **DRUG:** Placebo
- **DRUG:** Laquinimod
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02284568
- **Lead sponsor:** Teva Branded Pharmaceutical Products R&D, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-01-12
- **Primary completion:** 2017-05-04
- **Final completion:** 2017-10-01
- **Target enrollment:** 374 (ACTUAL)
- **Last updated:** 2022-03-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02284568

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02284568, "A Phase 2 Clinical Study in Subjects With Primary Progressive Multiple Sclerosis to Assess the Efficacy, Safety and Tolerability of Two Oral Doses of Laquinimod Either of 0.6 mg/Day or 1.5mg/Day (Experimental Drug) as Compared to Placebo". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02284568. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*